PATENT CLAIM ANALYSIS

Application Number: 15969651
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-10
Patent Classification: ["514", "262100"]

Abstract:
Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

Claim (Index 138):
The solid pharmaceutical formulation of  claim 130 , further comprising about 20-70% binder

Metadata:
- Claim Count in Document: 119.0
- Percentile: 93.0
- Lexical Diversity: 1.4375
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15659803', '15965114', '14091196', '13747322', '15054952']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8561456049845377
- 35 USC 102 Novelty (BERT): 0.5402184604486345
- Combined Prediction Score: 0.8245528905309475
- Mean Citation Score: 764.3889940000001
- Max Citation Score: 767.04364
- Similarity Product: 329.98435368095875

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test